Pharma Two B Ltd., a Rehovoth, Israel-based biopharmaceutical company focused on developing treatments for Parkinson’s disease, completed a $30m third round of financing.
The round was led by Israel Biotech Fund (IBF) with participation from aMoon and JVC and current investors JK&B and Generali Financial Holdings FCP-FIS SF2. In conjunction with the funding, Mr. Jeff Kindler, the former CEO and chairman of Pfizer and a member of Israel Biotech Fund’s Venture Advisory Team, will join Pharma Two B’s Board of Directors.
Led by Founder & Chairman Mr. Ehud Marom and CEO Dr. Nurit Livnah, Pharma Two B develops products in two therapeutic areas with great unmet needs. Its leading product is a combination drug for the treatment of early stage Parkinson’s disease.
The company intends to use the funds to complete the final pivotal phase III clinical trial needed to register P2B001 – its lead combination product for the treatment of Parkinson’s disease – and to expand its portfolio to include additional products.